Zenas BioPharma (ZBIO) Net Cash Flow (2023 - 2026)

Zenas BioPharma's Net Cash Flow history runs 4 years deep, the most recent figure standing at $389.9 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 416.41% year-over-year to $389.9 million; the TTM figure through Mar 2026 stood at $304.2 million (up 91.02% YoY), while the FY2025 annual figure was -$208.9 million, down 179.53% from the prior year.
• Net Cash Flow was $389.9 million for Q1 2026 at Zenas BioPharma, up from -$4.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $389.9 million in Q1 2026 to a low of -$152.3 million in Q2 2025.
• Historically, Net Cash Flow has averaged $42.8 million across 4 years, with a median of -$10.1 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow plunged 524.31% in 2025, then surged 416.41% in 2026.
• A 4-year view of Net Cash Flow shows it stood at -$15.4 million in 2023, then plunged by 163.43% to -$40.4 million in 2024, then surged by 87.8% to -$4.9 million in 2025, then jumped by 8000.59% to $389.9 million in 2026.
• The last three Net Cash Flow figures came in at $389.9 million (Q1 2026), -$4.9 million (Q4 2025), and $71.5 million (Q3 2025), per Business Quant data.